Cowen and Company’s ResMed RMD Stock Holding History

Cowen and Company’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,600	Closed	-$351K	–	572
2019 Q3	$351K	Buy	+2,600	New	+$341K	0.09%	167

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cowen and Company's RMD Position: Q4 2019 in Review

Cowen and Company sold out of ResMed (RMD) in Q4 2019, closing a stake of 2,600 shares — an estimated $351K sold.

Cowen and Company first reported a position in RMD in Q3 2019 and held it in 1 quarter. The position peaked at $351K in Q3 2019. 559 funds tracked by Wall St. Rank hold RMD as of Q4 2019.

Cowen and Company reported no remaining ResMed position as of Q4 2019 after selling out during the quarter.
Cowen and Company sold 2,600 ResMed shares in Q4 2019, an estimated $351K.
Cowen and Company first reported a position in ResMed in Q3 2019 and held it in 1 quarter.
Cowen and Company's ResMed position peaked at $351K in Q3 2019.
559 funds tracked by Wall St. Rank held ResMed as of Q4 2019.

Based on Cowen and Company's 13F filing for Q4 2019, filed 11 Feb 2020.